SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Sharma Akshay)) hsvcat:3
 

Search: (WFRF:(Sharma Akshay)) hsvcat:3 > An adapted European...

  • Jimenez, Antonio M. JimenezUniv Miami, Miller Sch Med, Div Transplantat & Cellular Therapy, Miami, FL 33136 USA. (author)

An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • 2021-09-28
  • Springer Nature,2021
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-470111
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-470111URI
  • https://doi.org/10.1038/s41409-021-01450-3DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:147791575URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Cytogenetic and molecular abnormalities are known to influence post-transplant outcomes in acute myeloid leukemia (AML) but data assessing the prognostic value of combined genetic models in the HCT setting are limited. We developed an adapted European LeukemiaNet (aELN) risk classification based on available genetic data reported to the Center for International Blood and Marrow Transplant Research, to predict post-transplant outcomes in 2289 adult AML patients transplanted in first remission, between 2013 and 2017. Patients were stratified according to aELN into three groups: favorable (Fav, N = 181), intermediate (IM, N = 1185), and adverse (Adv, N = 923). Univariate analysis demonstrated significant differences in 2-year overall survival (OS) (Fav: 67.7%, IM: 64.9% and Adv: 53.9%; p < 0.001); disease-free survival (DFS) (Fav: 57.8%, IM: 55.5% and Adv: 45.3; p < 0.001) and relapse (Fav: 28%, IM: 27.5% and Adv: 37.5%; p < 0.001). Multivariate analysis (MVA) revealed no differences in outcomes between the Fav and IM groups, thus they were combined. On MVA, patients in the Adv risk group had the highest risk of relapse (HR 1.47 p <= 0.001) and inferior DFS (HR 1.35 p < 0.001) and OS (HR 1.39 p < 0.001), even using myeloablative conditioning or in those without the pre-HCT measurable-residual disease. Novel approaches to mitigate relapse in this high-risk group are urgently needed.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • De Lima, MarcosUniv Hosp Case Med Ctr, Seidman Canc Ctr, Dept Med, Cleveland, OH USA. (author)
  • Komanduri, Krishna, VUniv Miami, Miller Sch Med, Div Transplantat & Cellular Therapy, Miami, FL 33136 USA. (author)
  • Wang, Trent P.Univ Miami, Miller Sch Med, Div Transplantat & Cellular Therapy, Miami, FL 33136 USA. (author)
  • Zhang, Mei-JieMed Coll Wisconsin, Dept Med, CIBMTR Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. (author)
  • Chen, KarenMed Coll Wisconsin, Dept Med, CIBMTR Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Abdel-Azim, HishamUniv Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA 90007 USA. (author)
  • Abid, Muhammad BilalMed Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, Div Infect Dis, Milwaukee, WI 53226 USA. (author)
  • Aljurf, MahmoudKing Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia. (author)
  • Alkhateeb, HassanMayo Clin Rochester, Rochester, MN USA. (author)
  • Assal, AmerColumbia Univ, Dept Med, Irving Med Ctr, Bone Marrow Transplant & Cell Therapy Program, New York, NY USA. (author)
  • Bacher, UlrikeUniv Bern, Bern Univ Hosp, Dept Hematol, Inselspital, Bern, Switzerland. (author)
  • Baron, FredericCHU, Liege, Belgium.;Univ Liege, Liege, Belgium. (author)
  • Battiwalla, MinooSarah Cannon Blood Canc Network, Nashville, TN USA. (author)
  • Beitinjaneh, AmerUniv Miami, Miller Sch Med, Div Transplantat & Cellular Therapy, Miami, FL 33136 USA. (author)
  • Bejanyan, NelliH Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA. (author)
  • Bhatt, Vijaya RajUniv Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA. (author)
  • Byrne, MichaelVanderbilt Univ, Med Ctr, Nashville, TN USA. (author)
  • Cahn, Jean-YvesUniv Grenoble Alpes, Dept Hematol, CHU Grenoble Alpes, Grenoble, France. (author)
  • Cairo, MitchellNew York Med Coll, Dept Pediat, Div Pediat Hematol Oncol & Stem Cell Transplantat, Valhalla, NY 10595 USA. (author)
  • Castillo, PaulUF Hlth Shands Childrens Hosp, Gainesville, FL USA. (author)
  • Copelan, EdwardAtrium Hlth, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA. (author)
  • DeFilipp, ZachariahMassachusetts Gen Hosp, Lematopoiet Cell Transplant & Cellular Therapy Pr, Boston, MA 02114 USA. (author)
  • Diaz Perez, Miguel AngelHosp Infantil Univ Nino Jesus, Dept Hematol Oncol, Madrid, Spain. (author)
  • Elsawy, MahmoudDalhousie Univ, Dept Med, Div Hematol, Halifax, NS, Canada. (author)
  • Gale, Robert PeterImperial Coll London, Haematol Res Ctr, Dept Immunol & Inflammat, London, England. (author)
  • George, BijuChristian Med Coll & Hosp, Vellore, Tamil Nadu, India. (author)
  • Grunwald, Michael R.Atrium Hlth, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA. (author)
  • Hildebrandt, Gerhard C.Univ Kentucky, Markey Canc Ctr, Lexington, KY USA. (author)
  • Hogan, William J.Mayo Clin, Div Hematol BMT, Rochester, MN USA. (author)
  • Kanakry, Christopher G.NCI, Expt Transplantat & Immunotherapy Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. (author)
  • Kansagra, AnkitUT Southwestern Med Ctr, Blood & Marrow Transplant Program, Dallas, TX USA. (author)
  • Kharfan-Dabaja, Mohamed A.Mayo Clin, Div Hematol Oncol, Blood & Marrow Transplantat Program, Jacksonville, FL USA. (author)
  • Khera, NanditaMayo Clin, Dept Hematol Oncol, Phoenix, AZ USA. (author)
  • Krem, Maxwell M.Univ Kentucky, Coll Med, Markey Canc Ctr, Lexington, KY USA. (author)
  • Lazaryan, AleksandrH Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA. (author)
  • Maakaron, JosephUniv Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Box 736 UMHC, Minneapolis, MN 55455 USA. (author)
  • Martino, RodrigoHosp Santa Creu & Sant Pau, Div Clin Hematol, Barcelona, Spain. (author)
  • McGuirk, JosephUniv Kansas Canc Ctr, Div Hematol Malignancies & Cellular Therapeut, Minneapolis, MN USA. (author)
  • Michelis, Fotios, VPrincess Margaret Canc Ctr, Allogene Blood & Marrow Transplant Program, Toronto, ON, Canada. (author)
  • Milone, GiuseppeAzienda Osped Univ Policlin San Marco, Catania, Italy. (author)
  • Mishra, AsmitaH Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA. (author)
  • Murthy, Hemant S.Mayo Clin, Div Hematol Oncol, Blood & Marrow Transplantat Program, Jacksonville, FL USA. (author)
  • Mussetti, AlbertoInst Catala Oncol Hosp, Hematol Dept, Barcelona, Spain.;IDIBELL Inst Catala Oncol, Lhospitalet De Llobregat, El Prat De Llob, Spain. (author)
  • Nathan, SunitaRush Univ, Med Ctr, Sect Bone Marrow Transplant & Cell Therapy, Chicago, IL USA. (author)
  • Nishihori, TaigaH Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA. (author)
  • Olsson, RichardUppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Stockholm, Sweden.(Swepub:uu)riols677 (author)
  • Palmisiano, NeilThomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA. (author)
  • Patel, SagarUniv Utah, Huntsman Canc Inst, Blood & Marrow Transplant Program, Salt Lake City, UT USA. (author)
  • Saad, AymanOhio State Univ, Div Hematol, Columbus, OH 43210 USA. (author)
  • Seo, SachikoDokkyo Med Univ, Dept Hematol & Oncol, Mibu, Tochigi, Japan. (author)
  • Sharma, AkshaySt Jude Childrens Res Hosp, Dept Bone Marrow Transplantat & Cellular Therapy, 332 N Lauderdale St, Memphis, TN 38105 USA. (author)
  • Solh, MelhemNorthside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA. (author)
  • Verdonck, Leo F.Isala Clin, Dept Hematol Oncol, Zwolle, Netherlands. (author)
  • Wirk, BaldeepPenn State Canc Inst, Bone Marrow Transplant Program, Hershey, PA USA. (author)
  • Yared, Jean A.Univ Maryland, Dept Med, Greenebaum Comprehens Canc Ctr, Blood & Marrow Transplantat Program,Div Hematol O, Baltimore, MD 21201 USA. (author)
  • Litzow, MarkMayo Clin Rochester, Div Hematol, Rochester, MN USA.;Mayo Clin Rochester, Transplant Ctr, Rochester, MN USA. (author)
  • Kebriaei, PartowUniv Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX 77030 USA. (author)
  • Hourigan, Christopher S.NHLBI, Lab Myeloid Malignancies, NIH, Bldg 10, Bethesda, MD 20892 USA. (author)
  • Saber, WaelMed Coll Wisconsin, Dept Med, CIBMTR Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Weisdorf, DanielHosp Santa Creu & Sant Pau, Div Clin Hematol, Barcelona, Spain. (author)
  • Univ Miami, Miller Sch Med, Div Transplantat & Cellular Therapy, Miami, FL 33136 USA.Univ Hosp Case Med Ctr, Seidman Canc Ctr, Dept Med, Cleveland, OH USA. (creator_code:org_t)

Related titles

  • In:Bone Marrow Transplantation: Springer Nature56:12, s. 3068-30770268-33691476-5365

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view